Artivion, Inc. (NYSE:AORT – Get Free Report) SVP Jean Holloway sold 977 shares of the business’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $28.49, for a total value of $27,834.73. Following the transaction, the senior vice president owned 184,118 shares in the company, valued at $5,245,521.82. This represents a 0.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Artivion Trading Down 0.6%
Artivion stock opened at $28.48 on Friday. The business has a 50 day moving average price of $24.10 and a two-hundred day moving average price of $30.60. The company has a quick ratio of 2.51, a current ratio of 3.47 and a debt-to-equity ratio of 0.82. Artivion, Inc. has a 12 month low of $19.16 and a 12 month high of $48.25. The stock has a market cap of $1.39 billion, a price-to-earnings ratio of -406.77 and a beta of 1.25.
Artivion (NYSE:AORT – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter. The company had revenue of $125.76 million for the quarter, compared to analyst estimates of $119.99 million. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%. As a group, equities analysts forecast that Artivion, Inc. will post 0.45 EPS for the current year.
Analysts Set New Price Targets
Get Our Latest Stock Analysis on Artivion
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of AORT. BlackRock Inc. acquired a new stake in shares of Artivion in the 2nd quarter valued at $149,965,000. Conestoga Capital Advisors LLC acquired a new stake in shares of Artivion during the 1st quarter worth about $43,044,000. Summit Partners Public Asset Management LLC bought a new position in Artivion during the 4th quarter valued at about $39,401,000. Invesco Ltd. lifted its holdings in Artivion by 211.9% during the 4th quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock valued at $50,228,000 after purchasing an additional 748,119 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in Artivion by 144.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 537,375 shares of the company’s stock valued at $24,510,000 after buying an additional 317,518 shares in the last quarter. 86.37% of the stock is currently owned by institutional investors and hedge funds.
About Artivion
Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.
Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.
Read More
- Five stocks we like better than Artivion
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.
